Abatacept, cenicriviroc, or infliximab does not decrease time to recovery for hospitalized patients with COVID-19 pneumonia
1. There was no statistically significant difference in recovery time in patients with COVID-19 pneumonia using treatment with abatacept, cenicriviroc, or infliximab compared to standard care. 2. Safety assessment endpoints showed no significant difference between the trial drugs and placebo, as both groups had a similar incidence of serious adverse events (SAE). Evidence Rating Level:
Rating Level Designing Master Protocols Covid 19 Pneumonia Sars Cov2 2 Chronic Disease Infectious Disease
Source: 2minutemedicine.com